Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group

What Was Tested

This randomized controlled trial paper looks at Leuprolide in the context of endometriosis.

Who Took Part

PubMed indexes the participants as adults, women only.

Two hundred and one patients were enrolled in this multicenter, randomized, double-blind, 1-year trial.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Leuprolide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Leuprolide.

A placebo (an inactive look-alike) gave the Leuprolide group a baseline to be compared against.

More than one site took part, so the participants came from several places.

Pelvic pain scores were assessed monthly, and bone density was measured after 24 and 52 weeks.

What Was Measured

The subject headings attached to it are Bone Density, Cohort Studies, Endometriosis, Equilin, Estradiol, Gonadotropin-Releasing Hormone and Leuprolide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Leuprolide in people with endometriosis.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1998 (Obstetrics and gynecology), a journal based in United States.

More context: the Leuprolide compound page, Endometriosis research.